{"id":353,"date":"2021-11-26T08:54:55","date_gmt":"2021-11-26T07:54:55","guid":{"rendered":"https:\/\/semmelweis.hu\/tmk\/?page_id=353"},"modified":"2025-11-20T14:34:57","modified_gmt":"2025-11-20T13:34:57","slug":"kovacs-emoke-henrietta","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/tmk\/2021\/11\/26\/kovacs-emoke-henrietta\/","title":{"rendered":"Kov\u00e1cs Em\u0151ke Henrietta"},"content":{"rendered":"

\"\"<\/p>\n

FUNDENI CLINICAL INSTITUTE, DEPARTMENT OF ANESTHESIOLOGY, BUCHAREST<\/h4>\n
\n
TOPIC<\/strong><\/div>\n

Critical care – COVID-19.<\/span><\/p>\n<\/div>\n

\n
VISION<\/strong><\/div>\n

Implement new modalities to modify the thromboinflammatory process by further elucidating the underlying mechanisms.<\/span><\/p>\n<\/div>\n

\n
MISSION<\/strong><\/div>\n

Unveil the details of the crosstalk between the inflammatory response and hemostasis in critically ill patients.<\/span><\/p>\n<\/div>\n

\n
PROJECT TITLE 1<\/strong><\/div>\n

Higher-dose anticoagulation cannot prevent disease progression in COVID-19 patients: a systematic review and meta-analysis.<\/span><\/p>\n<\/div>\n

\n
PROJECT TITLE 2<\/strong><\/div>\n

Effectiveness and safety of fibrinolytic therapy in critically ill COVID-19 patients with ARDS: systematic review and a prospective meta-analysis.<\/span><\/p>\n<\/div>\n

\n
PROJECT TITLE 3<\/strong><\/div>\n

Effectiveness and safety of fibrinolytic therapy in critically ill COVID-19 patients with ARDS: an explorative registry analysis.<\/span><\/p>\n<\/div>\n

\n
PROJECT TITLE 4<\/strong><\/div>\n

Association between immunomodulation with interleukin-6 antagonists and the coagulation system in critically ill COVID-19 patients: a prospective observational study.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FUNDENI CLINICAL INSTITUTE, DEPARTMENT OF ANESTHESIOLOGY, BUCHAREST TOPIC Critical care – COVID-19. VISION Implement new modalities to modify the thromboinflammatory process by further elucidating the underlying mechanisms. MISSION Unveil the details of the crosstalk between the inflammatory response and hemostasis in critically ill patients. PROJECT TITLE 1 Higher-dose anticoagulation cannot prevent disease progression in COVID-19 …<\/p>\n","protected":false},"author":101929,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[7,46],"tags":[8],"class_list":["post-353","post","type-post","status-publish","format-standard","hentry","category-phd-hallgato","category-year-3-4-5-critical-care-cardiology","tag-cardiology-icu"],"acf":[],"_links":{"self":[{"href":"https:\/\/semmelweis.hu\/tmk\/wp-json\/wp\/v2\/posts\/353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/semmelweis.hu\/tmk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/semmelweis.hu\/tmk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/tmk\/wp-json\/wp\/v2\/users\/101929"}],"replies":[{"embeddable":true,"href":"https:\/\/semmelweis.hu\/tmk\/wp-json\/wp\/v2\/comments?post=353"}],"version-history":[{"count":7,"href":"https:\/\/semmelweis.hu\/tmk\/wp-json\/wp\/v2\/posts\/353\/revisions"}],"predecessor-version":[{"id":8557,"href":"https:\/\/semmelweis.hu\/tmk\/wp-json\/wp\/v2\/posts\/353\/revisions\/8557"}],"wp:attachment":[{"href":"https:\/\/semmelweis.hu\/tmk\/wp-json\/wp\/v2\/media?parent=353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/semmelweis.hu\/tmk\/wp-json\/wp\/v2\/categories?post=353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/semmelweis.hu\/tmk\/wp-json\/wp\/v2\/tags?post=353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}